Genexine, Inc.

KOSDAQ 095700.KQ

Genexine, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 40,476,951

Genexine, Inc. Shares (Diluted, Weighted) is 40,476,951 for the year ending December 31, 2023, a -4.61% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Genexine, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 42,432,062, a 22.30% change year over year.
Genexine, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 34,695,815, a 2.14% change year over year.
Genexine, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 33,968,428, a 14.41% change year over year.
Genexine, Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 29,689,580, a 4.89% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

KOSDAQ: 095700.KQ

Genexine, Inc.

CEO	Dr. Jungwon Woo Ph.D.
IPO Date	Sept. 15, 2009
Location	South Korea
Headquarters	Korea Bio Park Building B
Employees	86
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.

Key trends

Past 5 years